{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T20:21:06.122461+00:00","company":{"ticker":"ABUS","cik":1447028,"company_name":"Arbutus Biopharma Corp"},"pagination":{"limit":100,"returned":40,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Moderna, Inc. and ModernaTx, Inc.","detail":"settlement","count":1,"first_seen":"2026-03-03T23:59:59+00:00","last_seen":"2026-03-03T23:59:59+00:00","evidence_fact_ids":[30306]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"812cee2d4ca973c6eb9f61e2fd3f5be4163ff523","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-27T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-26","outcome":"passed","proposal_text":"Approval of appointment of Ernst & Young LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"2,806,946","votes_against":"2,123,916","votes_for":"164,372,596","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved Approval of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-26 meeting.","evidence_excerpt":"Proposal 4. To approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Votes Abstained Broker Non-Votes 164,372,596 2,123,916 2,806,946 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001447028-26-000024","anchor_url":"https://secwatch.observer/filing/0001447028-26-000024#claim-812cee2d4ca973c6eb9f61e2fd3f5be4163ff523","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ce94f4349e3cc3da8d829412e71ce875bc719c0f","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-27T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-26","outcome":"passed","proposal_text":"Non-binding advisory vote on compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"22,829,831","subject":null,"votes_abstain":"512,660","votes_against":"8,331,760","votes_for":"137,629,207","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-26 meeting.","evidence_excerpt":"Proposal 3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular: Votes For Votes Against Votes Abstained Broker Non-Votes 137,629,207 8,331,760 512,660 22,829,831","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001447028-26-000024","anchor_url":"https://secwatch.observer/filing/0001447028-26-000024#claim-ce94f4349e3cc3da8d829412e71ce875bc719c0f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6c1390cab067a904b0f6657c4662a22d7887c6dd","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-27T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-26","outcome":"passed","proposal_text":"Approval of the adoption of the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"22,829,831","subject":null,"votes_abstain":"188,253","votes_against":"7,408,185","votes_for":"138,877,189","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved Approval of the adoption of the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan at the 2026-05-26 meeting.","evidence_excerpt":"Proposal 2. To approve the adoption of the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan: Votes For Votes Against Votes Abstained Broker Non-Votes 138,877,189 7,408,185 188,253 22,829,831","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001447028-26-000024","anchor_url":"https://secwatch.observer/filing/0001447028-26-000024#claim-6c1390cab067a904b0f6657c4662a22d7887c6dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f2f3e92aae5bab6ae2a43cf2aedcae6dc856d050","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-27T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-26","outcome":"passed","proposal_text":"Election of five director nominees","proposal_type":"director_election","results":[{"broker_non_votes":"22,829,831","subject":"Lindsay Androski, JD, MBA, CFA","votes_abstain":null,"votes_against":null,"votes_for":"136,780,089","votes_withheld":"9,693,538"},{"broker_non_votes":"22,829,831","subject":"Robert Alan Beardsley","votes_abstain":null,"votes_against":null,"votes_for":"138,456,756","votes_withheld":"8,016,871"},{"broker_non_votes":"22,829,831","subject":"Joseph Bishop","votes_abstain":null,"votes_against":null,"votes_for":"137,372,240","votes_withheld":"9,101,387"},{"broker_non_votes":"22,829,831","subject":"Matthew Gline","votes_abstain":null,"votes_against":null,"votes_for":"126,670,273","votes_withheld":"19,803,354"},{"broker_non_votes":"22,829,831","subject":"Roger Sawhney, MD","votes_abstain":null,"votes_against":null,"votes_for":"139,299,405","votes_withheld":"7,174,222"}]},"claim":"Arbutus Biopharma Corp shareholders approved Election of five director nominees at the 2026-05-26 meeting.","evidence_excerpt":"Proposal 1. To elect the five (5) director nominees named in the Proxy Statement/Circular each to serve until the 2027 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Nominee Votes For Votes Withheld Broker Non-Votes Lindsay Androski, JD, MBA, CFA 136,780,089 9,693,538 22,829,831 Robert Alan Beardsley 138,456,756 8,016,871 22,829,831 Joseph Bishop 137,372,240 9,101,387 22,829,831 Matthew Gline 126,670,273 19,803,354 22,829,831 Roger Sawhney, MD 139,299,405 7,174,222 22,829,831","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001447028-26-000024","anchor_url":"https://secwatch.observer/filing/0001447028-26-000024#claim-f2f3e92aae5bab6ae2a43cf2aedcae6dc856d050","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm"},{"fact_type":"earnings_release","fact_key":"9a6d46b2e3a8c55955c3df71104d8d5a84175f2b","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-13T11:31:16+00:00","payload":{"eps_text":"income of $0.88 per basic and $0.87 per diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8","period_text":"quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.","evidence_excerpt":"Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001171843-26-003346","anchor_url":"https://secwatch.observer/filing/0001171843-26-003346#claim-9a6d46b2e3a8c55955c3df71104d8d5a84175f2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm"},{"fact_type":"earnings_release","fact_key":"72c9a989b0c96e942c1bd6bcf822faa832dd1c1d","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-13T11:31:16+00:00","payload":{"eps_text":"income of $0.88 per basic and $0.87 per diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$169.7 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":"$179.1 million"},"claim":"Arbutus Biopharma Corp reported first quarter ended March 31, 2026 results: revenue $179.1 million, net income $169.7 million, EPS income of $0.88 per basic and $0.87 per diluted common share.","evidence_excerpt":"Revenue Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001171843-26-003346","anchor_url":"https://secwatch.observer/filing/0001171843-26-003346#claim-72c9a989b0c96e942c1bd6bcf822faa832dd1c1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm"},{"fact_type":"earnings_release","fact_key":"dc65558b0b252b082970718ef56b0960ffbb0e37","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-03-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2025","report_date":"2026-03-23","result_type":"reported_results","revenue_text":"$14.1 million"},"claim":"Arbutus Biopharma Corp reported the fourth quarter and year ended December 31, 2025 results: revenue $14.1 million.","evidence_excerpt":"one-time payments related to its restructuring efforts. This was partially offset by $5.5 million of proceeds from the exercise of stock options. Revenue Total revenue was $14.1 million for the year ended December 31, 2025, compared to $6.2 million for the same period in 2024. The increase of $7.9 million was due to the recognition of all previously-deferred","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-26-001838","anchor_url":"https://secwatch.observer/filing/0001171843-26-001838#claim-dc65558b0b252b082970718ef56b0960ffbb0e37","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm"},{"fact_type":"material_agreement","fact_key":"8fc31b6220906dce47f4a406775c43f7bf172d2d","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2026-03-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Moderna, Inc. and ModernaTx, Inc. (together, Moderna)","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":"$950.0 million noncontingent lump sum payment"},"claim":"Arbutus Biopharma Corp entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, Moderna) valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-26-001299","anchor_url":"https://secwatch.observer/filing/0001171843-26-001299#claim-8fc31b6220906dce47f4a406775c43f7bf172d2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm"},{"fact_type":"executive_change","fact_key":"93289701b1","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"terminated without cause","action_category":"departure","departure_tone":"termination","effective_date":"2025-03-27","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"David Hastings departed as Chief Financial Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001447028-25-000093","anchor_url":"https://secwatch.observer/filing/0001447028-25-000093#claim-93289701b1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm"},{"fact_type":"executive_change","fact_key":"72014df024","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"terminated without cause","action_category":"departure","departure_tone":"termination","effective_date":"2025-03-25","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Karen Sims departed as Chief Medical Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001447028-25-000093","anchor_url":"https://secwatch.observer/filing/0001447028-25-000093#claim-72014df024","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm"},{"fact_type":"executive_change","fact_key":"25ffe201a5","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":null,"action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-24","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Lindsay Androski was appointed as Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-25ffe201a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"cb52a38c7f","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-24","interim":false,"role":"Chairperson of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Lindsay Androski was appointed as Chairperson of the Board at Arbutus Biopharma Corp.","evidence_excerpt":"appointed Ms. Androski as chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-cb52a38c7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"c1d90953b3","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Melissa V. Rewolinski resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Melissa V. Rewolinski, Ph.D.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-c1d90953b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"a6603cf303","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Meyers resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"James Meyers","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-a6603cf303","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"c5ece88909","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Keith Manchester resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Keith Manchester, M.D.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-c5ece88909","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"accfbf2ca9","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard C. Henriques resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Richard C. Henriques","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-accfbf2ca9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"0039c3ab3c","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Daniel Burgess resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Daniel Burgess","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-0039c3ab3c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"dbcb8bed68","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael J. McElhaugh resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Michael J. McElhaugh","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-dbcb8bed68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"add14f833b","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Frank Torti resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Frank Torti, M.D., chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-001049","anchor_url":"https://secwatch.observer/filing/0001171843-25-001049#claim-add14f833b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm"},{"fact_type":"executive_change","fact_key":"87f7ac0b65","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-10-11T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-12-31","interim":false,"role":"Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Michael J. Sofia retired as Chief Scientific Officer at Arbutus Biopharma Corp.","evidence_excerpt":"As previously disclosed, Michael J. Sofia announced his retirement as Chief Scientific Officer of Arbutus Biopharma, Inc. (the “Company”), a subsidiary of Arbutus Biopharma Corporation, effective December 31, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001447028-24-000084","anchor_url":"https://secwatch.observer/filing/0001447028-24-000084#claim-87f7ac0b65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000084/0001447028-24-000084-index.htm"},{"fact_type":"earnings_release","fact_key":"c9cd395fd43398be4906ce186034a12d4944ca23","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and certain other information.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001171843-24-002453","anchor_url":"https://secwatch.observer/filing/0001171843-24-002453#claim-c9cd395fd43398be4906ce186034a12d4944ca23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm"},{"fact_type":"executive_change","fact_key":"4ca0a1d83f","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-05-02T23:59:59+00:00","payload":{"action":"notified retirement","action_category":"departure","departure_tone":"retirement","effective_date":"2024-12-31","interim":false,"role":"Chief Scientific Officer","role_category":"other","successor_name":null,"successor_named":false},"claim":"Michael Sofia departed as Chief Scientific Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On May 1, 2024, Dr. Michael Sofia notified Arbutus Biopharma Corporation (the “Company”) of his retirement as Chief Scientific Officer of the Company, effective December 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-002452","anchor_url":"https://secwatch.observer/filing/0001171843-24-002452#claim-4ca0a1d83f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324002452/0001171843-24-002452-index.htm"},{"fact_type":"earnings_release","fact_key":"4b4f8695a30399a909e66e8b529a487460f25af6","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-02-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Fourth quarter and year ended December 31, 2023","report_date":"2024-02-29","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported financial results for Fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023 and certain other information.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-001068","anchor_url":"https://secwatch.observer/filing/0001171843-24-001068#claim-4b4f8695a30399a909e66e8b529a487460f25af6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm"},{"fact_type":"executive_change","fact_key":"963ab4e3e7","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-01","interim":true,"role":"Interim President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Michael J. McElhaugh was appointed as Interim President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On January 1, 2024 (the “Effective Date”), Michael J. McElhaugh, the Company’s Interim President and Chief Executive Officer, and Arbutus entered into that certain Fourth Amendment to Executive Employment Agreement","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001447028-24-000006","anchor_url":"https://secwatch.observer/filing/0001447028-24-000006#claim-963ab4e3e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm"},{"fact_type":"executive_change","fact_key":"a4404cfb86","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-12-31","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Michael J. McElhaugh","successor_named":true},"claim":"William H. Collier retired as Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"William H. Collier retired as Chief Executive Officer of Arbutus Biopharma Corporation (the “Company”), effective December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001447028-24-000006","anchor_url":"https://secwatch.observer/filing/0001447028-24-000006#claim-a4404cfb86","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm"},{"fact_type":"earnings_release","fact_key":"0e7851efc15114796c88bdae154f99e823a83f85","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-23-006796","anchor_url":"https://secwatch.observer/filing/0001171843-23-006796#claim-0e7851efc15114796c88bdae154f99e823a83f85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/0001171843-23-006796-index.htm"},{"fact_type":"executive_change","fact_key":"393eac47a2","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-01","interim":true,"role":"Interim President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Michael J. McElhaugh was appointed as Interim President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Board appointed Michael J. McElhaugh, Co-founder and Chief Operating Officer of the Company, as interim President and CEO, effective January 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-23-006795","anchor_url":"https://secwatch.observer/filing/0001171843-23-006795#claim-393eac47a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm"},{"fact_type":"executive_change","fact_key":"0bfe462d06","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-12-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Michael J. McElhaugh","successor_named":true},"claim":"William H. Collier retired as President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On November 1, 2023, William H. Collier informed Arbutus Biopharma Corporation (the “Company”) of his retirement as the Company’s Chief Executive Officer (“CEO”) and from the Board of Directors (the “Board”) of the Company, effective as of December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-23-006795","anchor_url":"https://secwatch.observer/filing/0001171843-23-006795#claim-0bfe462d06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm"},{"fact_type":"earnings_release","fact_key":"82186ba79aba6b112e3658a92c016c39dd2685f9","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"second quarter ended June 30, 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-23-004945","anchor_url":"https://secwatch.observer/filing/0001171843-23-004945#claim-82186ba79aba6b112e3658a92c016c39dd2685f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm"},{"fact_type":"executive_change","fact_key":"b912fb244d","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-07-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-07-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Melissa V. Rewolinski was appointed as Director at Arbutus Biopharma Corp.","evidence_excerpt":"appointed Melissa V. Rewolinski, PhD to the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-23-004458","anchor_url":"https://secwatch.observer/filing/0001171843-23-004458#claim-b912fb244d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/0001171843-23-004458-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2a8cbcabf9882dbefb67a1951fa1b76abb2d5b32","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-30","outcome":"passed","proposal_text":"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"378,400","votes_against":"786,900","votes_for":"125,655,064","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-30 meeting.","evidence_excerpt":"Proposal 4. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Votes For Votes Against Votes Abstained Broker Non-Votes 125,655,064 786,900 378,400 —","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001447028-23-000052","anchor_url":"https://secwatch.observer/filing/0001447028-23-000052#claim-2a8cbcabf9882dbefb67a1951fa1b76abb2d5b32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/0001447028-23-000052-index.htm"},{"fact_type":"shareholder_vote","fact_key":"981aeb54136885361c4f7a5d1116e245444cc2c0","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-30","outcome":"passed","proposal_text":"To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular","proposal_type":"say_on_pay","results":[{"broker_non_votes":"32,000,882","subject":null,"votes_abstain":"1,055,983","votes_against":"8,211,196","votes_for":"85,552,303","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular at the 2023-05-30 meeting.","evidence_excerpt":"Proposal 3. To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular: Votes For Votes Against Votes Abstained Broker Non-Votes 85,552,303 8,211,196 1,055,983 32,000,882","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001447028-23-000052","anchor_url":"https://secwatch.observer/filing/0001447028-23-000052#claim-981aeb54136885361c4f7a5d1116e245444cc2c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/0001447028-23-000052-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3b06e8fc63522a2259dd1c01b458e32981f7ea44","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-30","outcome":"passed","proposal_text":"To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 c","proposal_type":"equity_plan","results":[{"broker_non_votes":"32,000,882","subject":null,"votes_abstain":"210,674","votes_against":"8,972,164","votes_for":"85,636,644","votes_withheld":null}]},"claim":"Arbutus Biopharma Corp shareholders approved To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 c at the 2023-05-30 meeting.","evidence_excerpt":"Proposal 2. To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 common shares: Votes For Votes Against Votes Abstained Broker Non-Votes 85,636,644 8,972,164 210,674 32,000,882","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001447028-23-000052","anchor_url":"https://secwatch.observer/filing/0001447028-23-000052#claim-3b06e8fc63522a2259dd1c01b458e32981f7ea44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/0001447028-23-000052-index.htm"},{"fact_type":"shareholder_vote","fact_key":"29a72984f80e2a2039ee0698430b71c5821c8d15","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-30","outcome":"passed","proposal_text":"To elect the six director nominees named in the Proxy Statement/Circular each to serve until the 2024 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed","proposal_type":"director_election","results":[{"broker_non_votes":"32,000,882","subject":"Frank Torti, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"90,586,551","votes_withheld":"4,232,931"},{"broker_non_votes":"32,000,882","subject":"William H. Collier","votes_abstain":null,"votes_against":null,"votes_for":"92,373,962","votes_withheld":"2,445,520"},{"broker_non_votes":"32,000,882","subject":"Daniel Burgess","votes_abstain":null,"votes_against":null,"votes_for":"82,787,752","votes_withheld":"12,031,730"},{"broker_non_votes":"32,000,882","subject":"Richard C. Henriques","votes_abstain":null,"votes_against":null,"votes_for":"92,385,485","votes_withheld":"2,433,997"},{"broker_non_votes":"32,000,882","subject":"Keith Manchester, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"72,493,891","votes_withheld":"22,325,591"},{"broker_non_votes":"32,000,882","subject":"James Meyers","votes_abstain":null,"votes_against":null,"votes_for":"92,126,144","votes_withheld":"2,693,338"}]},"claim":"Arbutus Biopharma Corp shareholders approved To elect the six director nominees named in the Proxy Statement/Circular each to serve until the 2024 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed at the 2023-05-30 meeting.","evidence_excerpt":"Proposal 1. To elect the six director nominees named in the Proxy Statement/Circular each to serve until the 2024 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed: Nominee Votes For Votes Withheld Broker Non-Votes Frank Torti, M.D. 90,586,551 4,232,931 32,000,882 William H. Collier 92,373,962 2,445,520 32,000,882 Daniel Burgess 82,787,752 12,031,730 32,000,882 Richard C. Henriques 92,385,485 2,433,997 32,000,882 Keith Manchester, M.D. 72,493,891 22,325,591 32,000,882 James Meyers 92,126,144 2,693,338 32,000,882","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001447028-23-000052","anchor_url":"https://secwatch.observer/filing/0001447028-23-000052#claim-29a72984f80e2a2039ee0698430b71c5821c8d15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/0001447028-23-000052-index.htm"},{"fact_type":"earnings_release","fact_key":"fd3898aa4d0c69271b415590ea8b0d1b1366cf5a","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp updated its first quarter ended March 31, 2023 guidance (lowered).","evidence_excerpt":"On May 4, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023 and certain other information.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-23-002864","anchor_url":"https://secwatch.observer/filing/0001171843-23-002864#claim-fd3898aa4d0c69271b415590ea8b0d1b1366cf5a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/0001171843-23-002864-index.htm"},{"fact_type":"earnings_release","fact_key":"dae18baaa9ddbbda6acc22b2798fdefd7653f7ae","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-03-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2022","report_date":"2023-03-02","result_type":"reported_results","revenue_text":null},"claim":"Arbutus Biopharma Corp reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Arbutus Biopharma Corporation (the \"Company\") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 and certain other information.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-23-001339","anchor_url":"https://secwatch.observer/filing/0001171843-23-001339#claim-dae18baaa9ddbbda6acc22b2798fdefd7653f7ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm"},{"fact_type":"executive_change","fact_key":"dd64030664","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2023-01-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tram Tran resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"On January 23, 2023, Tram Tran, M.D. notified Arbutus Biopharma Corporation (the “Company”) of her decision to resign from the Board of Directors of the Company and all committees thereof, effective as of February 26, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-23-000518","anchor_url":"https://secwatch.observer/filing/0001171843-23-000518#claim-dd64030664","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323000518/0001171843-23-000518-index.htm"},{"fact_type":"earnings_release","fact_key":"d3650760b9acfc9287ad13659705c3dc00cbe8e7","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2022-11-09T23:59:59+00:00","payload":{"eps_text":"$0.12 per basic and diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$17.6 million","period_text":"third quarter ended September 30, 2022","report_date":"2022-11-09","result_type":"reported_results","revenue_text":"$6.0 million"},"claim":"Arbutus Biopharma Corp reported third quarter ended September 30, 2022 results: revenue $6.0 million, net income $17.6 million, EPS $0.12 per basic and diluted common share.","evidence_excerpt":"the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024. Revenue Total revenue was $6.0 million for the three months ended September 30, 2022 compared to $3.3 million for the same period in 2021. The increase of $2.7 million was due primarily to $2.3 million of revenue","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-22-007260","anchor_url":"https://secwatch.observer/filing/0001171843-22-007260#claim-d3650760b9acfc9287ad13659705c3dc00cbe8e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm"},{"fact_type":"executive_change","fact_key":"80268ceb44","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2022-10-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-01","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Mike McElhaugh was appointed as Chief Operating Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On October 18, 2022, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) appointed Mike McElhaugh, age 48, as the Company’s Chief Operating Officer, effective as of November 1, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001447028-22-000051","anchor_url":"https://secwatch.observer/filing/0001447028-22-000051#claim-80268ceb44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702822000051/0001447028-22-000051-index.htm"},{"fact_type":"executive_change","fact_key":"14576a6e27","cik":1447028,"ticker":"ABUS","company_name":"Arbutus Biopharma Corp","filed_at":"2021-11-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-11-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tram Tran was appointed as Director at Arbutus Biopharma Corp.","evidence_excerpt":"On November 9, 2021, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) (a) increased the size of the Board by one member such that the Board will thereafter consist of nine directors and (b) appointed Tram Tran, M.D. to the Board, to serve until the Company’s 2022 annual general meeting of shareholders and until her successor is duly appointed and qualified, or until her earlier death, resignation or removal.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-21-007863","anchor_url":"https://secwatch.observer/filing/0001171843-21-007863#claim-14576a6e27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/0001171843-21-007863-index.htm"}]}